No Data
No Data
Myriad Genetics First Quarter 2024 Earnings: Beats Expectations
Investors Bid Myriad Genetics (NASDAQ:MYGN) up US$428m Despite Increasing Losses YoY, Taking One-year Return to 36%
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can significantly boost your returns by picking above-average stocks. To wit, the Myriad
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks were slipping late Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing around 0.3%. The iShares Biotechnology ETF (IBB
Myriad Genetics Price Target Raised to $35.00/Share From $25.00 by Leerink Partners
Myriad Genetics Price Target Raised to $35.00/Share From $25.00 by Leerink Partners
Myriad Genetics Raised to Outperform From Market Perform by Leerink Partners
Myriad Genetics Raised to Outperform From Market Perform by Leerink Partners
Jaguar8 : Yes it’s quite disappointing that people don’t realize the importance of this.
TrytosaveabitOP Jaguar8: Yup! I have a volume and price move alerts set! Hehehe
Jaguar8 TrytosaveabitOP: What volume do you usually set like 1M?
TrytosaveabitOP Jaguar8: 300K in 3 minutes
Jaguar8 TrytosaveabitOP: Wow that is fast volume
View more comments...